The high expression level of LARP6 in the TNBC subtype compared to ER+ and HER2+ subtypes, which is correlated with a poor breast cancer survival rate, highlights its potential to be a TNBC specific prognostic marker and a TNBC specific therapeutic target. Here, LARP6 is linked to breast carcinoma.